
Eli Lilly and Company
An American multinational pharmaceutical company focused on discovering, developing, manufacturing, and commercializing prescription medicines.
Last updated November 14, 2026
AI crawler reads
170requests
8AI- OpenAI106
- Perplexity23
- Shape15
- Amazon14
- Anthropic8
- +34
- Profile
- 114
- Controversies
- 18
- JSON · MD
- 0
- First read
- Oct 29, 2026
- Latest read
- Nov 17, 2026
From this site's server log
Overview
Eli Lilly and Company, commonly known as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana. Colonel Eli Lilly founded the business in 1876 after working as a pharmacist and pharmaceutical chemist and serving as a Union officer during the American Civil War. From a small manufacturer of medicines, capsules, and pharmaceutical preparations, Lilly developed into a research-driven company with commercial operations and offices in numerous countries and products sold across much of the world. The company's early identity was shaped by an emphasis on manufacturing consistency, dosage accuracy, and more responsible pharmaceutical promotion than was common among nineteenth-century patent-medicine businesses. Early innovations included gelatin-coated pills and capsules, sugar-coated tablets, flavored medicines, improved production systems, and organized laboratory research. Lilly's transition toward modern scientific drug development accelerated in the early twentieth century, particularly after the recruitment of biochemist George Henry Alexander Clowes. His work helped establish relationships with academic researchers, including the University of Toronto scientists associated with insulin. Lilly subsequently became one of the first companies to manufacture insulin on a large commercial scale, launching Iletin in the United States in 1923. During the twentieth century, Lilly expanded from biological medicines into antibiotics, vaccines, endocrinology, oncology, neuroscience, immunology, and cardiovascular and metabolic treatments. It was involved in the production of the Salk polio vaccine and became an important producer of recombinant human insulin, including Humulin. The company also built substantial franchises in mental health through Prozac, Cymbalta, and Zyprexa, although those products later faced generic competition after patent expiry. Its research and licensing activities brought additional medicines, including the diabetes drug exenatide, which helped establish the GLP-1 class in commercial medicine. In the 2020s, Lilly's growth profile became increasingly associated with metabolic and diabetes medicines. Tirzepatide is marketed as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and related indications, subject to regulatory approval in individual markets. Other important products include the breast-cancer treatment Verzenio, the autoimmune medicine Taltz, the diabetes medicine Trulicity, the SGLT2 inhibitor Jardiance, insulin products, the migraine-prevention medicine Emgality, and several oncology and immunology therapies. The company operates as an innovation-led pharmaceutical business, relying on internal research, clinical development, manufacturing capacity, licensing, and acquisitions or collaborations to build its pipeline. Lilly's business is primarily prescription pharmaceuticals rather than consumer healthcare or medical devices. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience, pain, and cardiovascular or related metabolic disease. The company has made large investments in research, biologics manufacturing, injectable-product capacity, and supply infrastructure to support demand for newer medicines. Its stated commercial positioning combines scientific innovation, disease-focused research, global regulatory development, and large-scale manufacturing. Lilly remains headquartered in Indianapolis and continues to operate as an active, publicly traded pharmaceutical company.
History
Colonel Eli Lilly established Eli Lilly and Company in Indianapolis in 1876. Before founding the company, he had worked in drugstores and pharmaceutical manufacturing. He began with a small operation and a few employees, producing medicines such as quinine. His early business practices emphasized standardized formulations and dependable production at a time when pharmaceutical quality varied considerably. The company expanded its sales organization, moved into larger Indianapolis facilities, and incorporated in 1881. The business grew during the late nineteenth century under the leadership of Eli Lilly and, later, his son Josiah K. Lilly Sr. It manufactured pills, capsules, elixirs, fluid extracts, and other preparations. Lilly introduced or adopted practical improvements such as sugar coatings, flavoring, gelatin capsules, and more systematic manufacturing controls. By the 1890s, the company had developed specialized production facilities and a larger workforce. The Lilly family remained deeply involved in management, while also supporting civic, educational, and cultural institutions. A decisive transformation began in the early twentieth century. New buildings and production methods increased capacity, and the company began to organize research more formally. George Henry Alexander Clowes joined Lilly and helped connect the company with academic biomedical research. His involvement in the development and scale-up of insulin led to collaboration with University of Toronto researchers. Lilly commercialized Iletin in 1923, helping make insulin broadly available in the United States and establishing the company as a significant research-based pharmaceutical manufacturer. The company also adopted more efficient factory layouts and production systems, including straight-line manufacturing. Lilly expanded its biological and pharmaceutical activities through the following decades. It participated in the production of the polio vaccine developed through Jonas Salk's research and became an important producer of insulin. The company later helped pioneer recombinant-DNA human insulin with Humulin and expanded into additional injectable and biologic products. Its portfolio diversified into antibiotics, oncology, cardiovascular medicine, immunology, and central-nervous-system therapies. From the 1980s through the 2000s, Lilly achieved major commercial success in neuroscience and psychiatry. Prozac, launched in the late 1980s, became one of the best-known antidepressants in the world. Zyprexa and Cymbalta added important antipsychotic and antidepressant franchises. These medicines eventually faced generic competition, illustrating the importance of replacing mature products with new research discoveries. Lilly also entered and expanded in diabetes and metabolic disease, including the launch of exenatide in 2005, an early commercial GLP-1 receptor agonist. In the twenty-first century, the company broadened its oncology, immunology, diabetes, migraine, and autoimmune portfolios. Products such as Taltz, Trulicity, Verzenio, Jardiance, Emgality, Cyramza, and Olumiant became important components of the business. Tirzepatide represented a particularly significant development because it activates both GIP and GLP-1 pathways. Lilly markets it as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and other approved indications depending on jurisdiction. Lilly's contemporary strategy centers on research-led growth, clinical development, regulatory expansion, and investment in manufacturing capacity for complex injectable and biologic medicines. Its operations are international, although the United States remains its largest market. The company continues to manage the risks typical of the pharmaceutical industry, including clinical-trial uncertainty, regulatory scrutiny, patent expiry, pricing pressure, supply constraints, and competition from rival drug developers and generic manufacturers. It remains an active public company headquartered in Indianapolis.
- 2023
Zepbound launched
[3]Lilly introduced Zepbound, its tirzepatide brand for chronic weight management in the United States.
- 2022
Mounjaro launched
[3]Lilly launched tirzepatide as Mounjaro for type 2 diabetes in the United States.
- 2017
David Ricks becomes chief executive
[2]David A. Ricks became Lilly's chief executive, later also serving as chair.
- 2005
Exenatide reaches the market
[1]Lilly brought exenatide to market, helping establish the GLP-1 receptor agonist class in diabetes treatment.
- 1996
Zyprexa introduced
[1]Olanzapine was launched as Zyprexa for schizophrenia and related psychiatric indications.
- 1986
Prozac introduced
[1]Lilly launched fluoxetine under the Prozac brand, creating a major antidepressant franchise.
- 1955
Polio vaccine production
[1]Lilly became involved in large-scale production of the Salk polio vaccine.
- 1923
Iletin insulin commercialized
[1]Lilly began selling Iletin, one of the first commercially available insulin products in the United States.
- 1919
Formal research expansion begins
[1]The recruitment of biochemist George Henry Alexander Clowes helped move Lilly toward organized biochemical research and academic collaboration.
- 1881
Business incorporated
[1]The company incorporated and expanded its Indianapolis manufacturing and administrative operations.
Products and positioning
A research-intensive global pharmaceutical company positioned around innovative prescription medicines, especially in diabetes and obesity, oncology, immunology, and neuroscience.
Diabetes medicine · 2022
Mounjaro
Mounjaro is Lilly's brand for tirzepatide in type 2 diabetes. Tirzepatide is an injectable dual GIP and GLP-1 receptor agonist developed to improve glycemic control alongside diet and exercise. It became one of Lilly's central growth products and is marketed under a different brand for chronic weight management.
Obesity and metabolic medicine · 2023
Zepbound
Zepbound is Lilly's tirzepatide brand for chronic weight management in eligible adults, subject to local regulatory approvals. The product extends the company's metabolic-medicine franchise beyond diabetes and is also associated with research into related conditions such as obstructive sleep apnea.
Oncology medicine · 2017
Verzenio
Verzenio is the brand name for abemaciclib, a CDK4/6 inhibitor used in specified forms of hormone-receptor-positive, HER2-negative breast cancer. Its approved uses vary by market and treatment setting. The medicine is a major oncology product in Lilly's portfolio.
Diabetes medicine · 2014
Trulicity
Trulicity is dulaglutide, a once-weekly GLP-1 receptor agonist for type 2 diabetes. It is designed to improve blood-glucose control and has been an important product in Lilly's long-running diabetes franchise.
Immunology medicine · 2016
Taltz
Taltz is ixekizumab, an interleukin-17A inhibitor used for several inflammatory and autoimmune diseases, including specified forms of psoriasis and psoriatic arthritis. Its indications depend on regulatory approval and patient age or disease presentation.
Diabetes and cardiovascular medicine · 2014
Jardiance
Jardiance is empagliflozin, an SGLT2 inhibitor developed with Boehringer Ingelheim. It is used in type 2 diabetes and, depending on market authorization, certain heart-failure and chronic-kidney-disease settings.
Insulin · 1996
Humalog
Humalog is insulin lispro, a rapid-acting insulin analogue used to control blood glucose in people with diabetes. It is part of Lilly's longstanding insulin business and is supplied in several delivery formats and concentrations in different markets.
Insulin · 1982
Humulin
Humulin is Lilly's brand for recombinant human insulin. Introduced in the early era of biotechnology medicines, it represented a major step away from animal-derived insulin and remains available in multiple formulations.
Neurology medicine · 2018
Emgality
Emgality is galcanezumab, a monoclonal antibody targeting CGRP-related migraine biology. It is used for prevention of migraine and, in some jurisdictions, other headache disorders subject to local authorization.
Antidepressant · 1986
Prozac
Prozac is the former Lilly brand for fluoxetine, a selective serotonin reuptake inhibitor. It became a landmark antidepressant franchise after its introduction and is now widely available in generic form following loss of exclusivity.
Antidepressant and pain medicine · 2004
Cymbalta
Cymbalta is the former Lilly brand for duloxetine, a serotonin-norepinephrine reuptake inhibitor used in depression and several pain-related indications. The product has faced generic competition after patent expiry.
Antipsychotic · 1996
Zyprexa
Zyprexa is the former Lilly brand for olanzapine, an atypical antipsychotic used in specified psychiatric conditions. It was a major historical commercial product and is now also supplied by generic manufacturers.
Controversies
2025
Indiana sues Eli Lilly over alleged insulin price-fixing
Indiana filed a lawsuit in Lake County Superior Court on Dec. 31 alleging that Eli Lilly conspired with pharmacy benefit managers to artificially inflate insulin list prices through secret rebates, charging roughly $300 to $700 for some insulin products. Lilly said it has taken industry-leading steps to lower insulin costs, including capping out-of-pocket costs at $35 per month and cutting list prices by 70%.
2023
Eli Lilly and former employee agree to settle whistleblower lawsuit
Eli Lilly and former employee Amrit Mula agreed to settle a lawsuit in which Mula alleged that she was terminated after raising concerns about manufacturing practices and data falsification involving company drugs. Lilly said the resolution in no way admitted wrongdoing; settlement details were not disclosed in the article.
Marketing campaigns
- 2020Lilly and media partners announce Indy Day of Solidarity virtual event
US
Eli Lilly and Company, Indianapolis Recorder Newspaper, Radio One and WISH-TV announced the Indy Day of Solidarity virtual event, scheduled for June 13, 2020, to acknowledge racial injustice and encourage a call to action for lasting change.
- 2019Lilly launches insulin cost-saving awareness campaign
US
Eli Lilly launched an awareness campaign promoting cost-saving options for people who need help affording Lilly insulin. The campaign included an open letter published in newspapers and a digital advertising campaign planned to run later that month through March.
Brand decisions
2026
Lilly agrees to acquire Calytrix BioM&ABackground
Calytrix Bio announced a definitive agreement for Eli Lilly and Company to acquire it. Calytrix shareholders could receive up to $1.5 billion in cash, including an upfront payment and subsequent payments tied to clinical and regulatory milestones.
2023
Lilly completes acquisition of Versanis BioM&ABackground
Eli Lilly and Company completed its acquisition of clinical-stage biopharmaceutical firm Versanis Bio. The acquisition adds Versanis’ lead asset, bimagrumab, to Lilly’s portfolio.
Recent events
Lilly agrees to acquire Calytrix Bio[6]
Reported
Calytrix Bio announced a definitive agreement for Eli Lilly and Company to acquire it. Calytrix shareholders could receive up to $1.5 billion in cash, including an upfront payment and subsequent payments tied to clinical and regulatory milestones.
- Unconfirmed
Richter and Lilly enter licensing agreement for women’s health and cardiometabolic medicines[14]
Reported
Gedeon Richter entered into a licensing agreement with Eli Lilly and Company under which Richter will grant Lilly exclusive worldwide rights to develop, manufacture and commercialize jointly developed medicines for women’s health conditions and cardiometabolic diseases. A separate supply agreement covers the active pharmaceutical ingredient Estetrol (E4).
Lilly raises 2026 revenue outlook[15]
Reported
Eli Lilly and Company raised its 2026 revenue outlook to $91 billion-$92 billion from $85 billion-$87 billion. It also raised its non-GAAP performance-margin outlook and lowered its non-GAAP earnings-per-share forecast.
- Unconfirmed
Jitai Technology and Eli Lilly form an AI-LNP platform partnership[16]
Jitai Technology and Eli Lilly entered a strategic collaboration in which Jitai will use its AiLNP platform to develop LNP delivery technology, while Lilly will contribute resources in drug discovery, development, and commercialization.
- Unconfirmed
Pennsylvania sues insulin makers and PBMs over alleged insulin price collusion[9]
Pennsylvania sued Eli Lilly and Co., Novo Nordisk Inc., Sanofi-Aventis US LLC, and several PBMs, alleging that they colluded to raise insulin prices. The lawsuit seeks structural changes, restitution, and financial penalties.
- Unconfirmed
Caspian Therapeutics raises $50 million in financing led by BVF Partners[17]
Reported
Caspian Therapeutics has raised $50 million in financing led by BVF Partners, with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura and other investors. The proceeds are expected to fund IND-enabling work, an initial clinical proof-of-concept program and advancement of a second menin inhibitor candidate.
Ascidian Therapeutics and Eli Lilly announce kidney disease research collaboration[18]
Reported
Ascidian Therapeutics and Eli Lilly announced a global research collaboration and licensing agreement to discover and develop therapies for undisclosed monogenic kidney diseases. Lilly will receive exclusive, target-specific rights to Ascidian's RNA exon editing technology for the targets.
WHO Foundation and Lilly announce obesity-care collaboration[19]
Reported
The WHO Foundation announced a collaboration with Eli Lilly and Company, which is committing $1.68 million through 2029 to support efforts to assess and strengthen health systems for obesity prevention and care.
Indiana sues Eli Lilly over alleged insulin price-fixing[8]
Reported
Indiana filed a lawsuit in Lake County Superior Court on Dec. 31 alleging that Eli Lilly conspired with pharmacy benefit managers to artificially inflate insulin list prices through secret rebates, charging roughly $300 to $700 for some insulin products. Lilly said it has taken industry-leading steps to lower insulin costs, including capping out-of-pocket costs at $35 per month and cutting list prices by 70%.
- Unconfirmed
Zuellig Pharma completes acquisition of Cialis and Alimta brands[20]
Reported
Zuellig Pharma concluded the acquisition of the Cialis and Alimta brands from Eli Lilly through its wholly owned subsidiary Zanovex. The transaction covers eight ASEAN markets, and Zanovex will hold the trademarks and marketing authorisations for both brands.
Sources88 sources
- 1Eli Lilly and Companyen.wikipedia.org
- 2Lilly leadershiplilly.com
- 3Lilly news and releaseslilly.com
- 4Lilly and media partners announce Indy Day of Solidarity virtual eventprnewswire.com
- 5Lilly launches insulin cost-saving awareness campaignprnewswire.com
- 6Lilly agrees to acquire Calytrix Bioprnewswire.com
- 7Lilly completes acquisition of Versanis Biopharmaceutical-business-review.com
- 8Indiana sues Eli Lilly over alleged insulin price-fixingwfyi.org
- 9Indiana sues Eli Lilly over alleged insulin price-fixingncpa.org
- 10Indiana sues Eli Lilly over alleged insulin price-fixingyahoo.com
- 11Indiana sues Eli Lilly over alleged insulin price-fixinginsideindianabusiness.com
- 12Indiana sues Eli Lilly over alleged insulin price-fixingthedailyrecord.com
- 13Eli Lilly and former employee agree to settle whistleblower lawsuitmedscape.com
- 14Richter与Lilly就女性健康及心脏代谢疾病药物达成许可协议hungarytoday.hu
- 15礼来上调2026年营收展望econotimes.com
- 16剂泰科技与礼来达成AI-LNP平台合作stcn.com
- 17Caspian Therapeutics 完成5000万美元融资,BVF Partners 领投themarketsdaily.com
- 18Ascidian Therapeutics 与礼来宣布开展肾病研究合作finanznachrichten.de
- 19WHO基金会与Lilly宣布合作加强肥胖症护理finanznachrichten.de
- 20Zuellig Pharma完成收购Cialis与Alimta品牌pharmaceutical-business-review.com
- 21UpDoc宣布战略融资prnewswire.com
- 22礼来宣布推出 LillyDirectinsideindianabusiness.com
- 23FDA批准Jaypirca用于CLL/SLLonclive.com
- 24FDA 批准 Zepbound 用于慢性体重管理localnews8.com
- 25FDA 批准礼来 Omvoh 用于治疗溃疡性结肠炎prnewswire.com
- 26Mission BioCapital与礼来合作推出2023年Platinum Programprnewswire.com
- 27晶泰科技与礼来签署AI新药发现合作caijing.stardaily.com.cn
- 28Lilly 宣布降低胰岛素价格并将每月自付费用上限定为 35 美元wboi.org
- 29Lilly 宣布以折扣价格推出 Rezvoglarprnewswire.com
- 30PrescriberPoint宣布种子轮投资prnewswire.com
- 31Ramiven 获批用于额外的早期乳腺癌适应症thehindubusinessline.com
- 32FDA批准Retevmo新增适应症finanznachrichten.de
- 33FDA批准Retevmo新增适应症prnewswire.com
- 34FDA批准Mounjaro用于成人2型糖尿病prnewswire.com
- 35Artax Biopharma完成2,600万美元融资prnewswire.com
- 36NeoGenomics与Lilly合作推出肺癌检测项目clevelandstar.com
- 37FDA批准Jardiance用于成人心力衰竭患者finanznachrichten.de
- 38Arkuda Therapeutics 完成 6400 万美元 B 轮融资prnewswire.com
- 39Mozart Therapeutics宣布获得5500万美元A轮融资biospace.com
- 40FDA批准Verzenio用于辅助治疗早期乳腺癌finanznachrichten.de
- 41Healthcare Pharmaceuticals在孟加拉国推出Cyramzatbsnews.net
- 42礼来与Lycia签署合作及许可协议wishtv.com
- 43美纳里尼完成在中国收购希爱力品牌prnasia.com
- 44Arecor宣布与礼来开展制剂研究合作finance.yahoo.com
- 45Natco与Lilly签署Baricitinib许可协议equitybulls.com
- 46Cipla 与礼来签署巴瑞替尼许可协议business-standard.com
- 47Rigel与Lilly完成全球许可协议及合作prnewswire.com
- 48Elsevier在PharmaPendium推出更新版DDIRC 2.0finanznachrichten.de
- 49Lilly任命Anat Ashkenazi接任首席财务官insideindianabusiness.com
- 50礼来宣布 AK1780 授权协议insideindianabusiness.com
- 51礼来与中国性学会发布《夜问365》prnasia.com
- 52FDA批准礼来 Lyumjev 胰岛素insideindianabusiness.com
- 53FDA批准礼来的Lyumjev胰岛素finanznachrichten.de
- 54礼来承诺资金和志愿服务时间以应对种族不公ibj.com
- 55Lilly与合作伙伴共同举办印第安纳波利斯团结日活动news.radio-online.com
- 56礼来公布2019年第四季度及全年业绩prnewswire.com
- 57Eli Lilly将独家赞助CNN Films Presents播映thefutoncritic.com
- 58剂泰科技与礼来达成战略合作,共同推进组织特异性LNP递送技术finance.sina.com.cn
- 59礼来(LLY.US)又出手!最高15亿美元收购Calytrix,押注罕见血癌疗法finance.jrj.com.cn
- 60替尔泊肽前三季度揽437亿美元 礼来上调全年业绩指引 _ 东方财富网finance.eastmoney.com
- 61Eli Lilly Debuts Digital Healthcare Platform for Chronic Illness Patients | PYMNTS.compymnts.com
- 62Eli Lilly Launches Digital Health Care Platform to Help Patients With Chronic Diseasetheepochtimes.com
- 63Eli Lilly Launches LillyDirect To Help Patients Manage Health, Access Medicinesrttnews.com
- 64Eli Lilly launches service to connect patients with telehealth care, deliver medications to their homes - Local News 8localnews8.com
- 65Eli Lilly: FDA Approves Jardiance In Treatment Of Chronic Kidney Diseasefinanznachrichten.de
- 66FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drugnbcchicago.com
- 67FDA Approves Jaypirca for Pretreated CLL, SLL | CUREcuretoday.com
- 68FDA approves Lilly diabetes drug that helps patients lose weight - Indianapolis Business Journalibj.com
- 69FDA approves Lilly's diabetes drug for weight management - Indianapolis Business Journalibj.com
- 70FDA Approves Lilly's Mounjaro Injection For Type 2 Diabetes Treatmentfinanznachrichten.de
- 71FDA approves Lyumjev™ (insulin lispro-aabc injection), Lilly's new rapid-acting insulinprnewswire.com
- 72FDA Approves Mirikizumab (Omvoh) for Ulcerative Colitis | HCPLivehcplive.com
- 73FDA Approves Mounjaro as New Obesity Drug Zepboundtheepochtimes.com
- 74FDA Approves New Diet Drug Zepbound, a Version of the Diabetes Med Mounjarohealthday.com
- 75FDA approves NEW obesity drug Zepbound which helps people lose 50lbsdailymail.com
- 76FDA approves new version of diabetes drug Mounjaro for weight losslatimes.com
- 77FDA Approves Tirzepatide (Zepbound) for Chronic Weight Management | HCPLivehcplive.com
- 78FDA approves weight loss drug from Eli Lilly that helped people lose up to 52 poundsnbcnews.com
- 79Lilly Acquires Calytrix Bio To Advance Treatments For Essential Thrombocythemia And Myelofibrosisrttnews.com
- 80Lilly Appoints Anat Ashkenazi Chief Financial Officerprnewswire.com
- 81Lilly Launches Campaign To Raise Awarenesses Of Discount Insulinwboi.org
- 82Lilly launches online service that offers home delivery of weight-loss, diabetes, migraine drugs - Indianapolis Business Journalibj.com
- 83Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlookprnewswire.com
- 84Lilly Reports Second-Quarter Financial Results, Raises EPS Guidanceprnewswire.com
- 85Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progressprnewswire.com
- 86Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Resultsprnewswire.com
- 87Lilly Reports Third-Quarter Financial Results, Updates Guidanceprnewswire.com
- 88Zuellig Pharma acquires Cialis® (Tadalafil) and Alimta® (Pemetrexed) from Lilly in select ASEAN marketsmalaymail.com
Cite this profile: Cite the canonical profile. /brandpedia/eli-lilly-and-company · Editorial policy · How profiles are compiled